SI3134432T1 - MND promotor himernega antigenskega receptorja - Google Patents
MND promotor himernega antigenskega receptorjaInfo
- Publication number
- SI3134432T1 SI3134432T1 SI201531177T SI201531177T SI3134432T1 SI 3134432 T1 SI3134432 T1 SI 3134432T1 SI 201531177 T SI201531177 T SI 201531177T SI 201531177 T SI201531177 T SI 201531177T SI 3134432 T1 SI3134432 T1 SI 3134432T1
- Authority
- SI
- Slovenia
- Prior art keywords
- chimeric antigen
- antigen receptors
- mnd promoter
- promoter chimeric
- mnd
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001119—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001128—CD44 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461984561P | 2014-04-25 | 2014-04-25 | |
PCT/US2015/027539 WO2015164759A2 (en) | 2014-04-25 | 2015-04-24 | Mnd promoter chimeric antigen receptors |
EP15782739.5A EP3134432B1 (en) | 2014-04-25 | 2015-04-24 | Mnd promoter chimeric antigen receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3134432T1 true SI3134432T1 (sl) | 2021-01-29 |
Family
ID=54333432
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201531177T SI3134432T1 (sl) | 2014-04-25 | 2015-04-24 | MND promotor himernega antigenskega receptorja |
SI201531750T SI3689899T1 (sl) | 2014-04-25 | 2015-04-24 | MND promotor kimeričnih antigenskih receptorjev |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201531750T SI3689899T1 (sl) | 2014-04-25 | 2015-04-24 | MND promotor kimeričnih antigenskih receptorjev |
Country Status (25)
Country | Link |
---|---|
US (2) | US10774343B2 (sl) |
EP (3) | EP3134432B1 (sl) |
JP (2) | JP6538716B2 (sl) |
KR (2) | KR102021982B1 (sl) |
CN (2) | CN110938655A (sl) |
AU (3) | AU2015249390B2 (sl) |
BR (1) | BR112016024481A2 (sl) |
CA (1) | CA2946585C (sl) |
CY (2) | CY1122831T1 (sl) |
DK (2) | DK3689899T3 (sl) |
ES (2) | ES2899608T3 (sl) |
HR (2) | HRP20211910T1 (sl) |
HU (2) | HUE048898T2 (sl) |
IL (3) | IL296691B2 (sl) |
LT (2) | LT3134432T (sl) |
MX (2) | MX2016013964A (sl) |
NZ (1) | NZ725169A (sl) |
PL (2) | PL3134432T3 (sl) |
PT (2) | PT3134432T (sl) |
RS (2) | RS60106B1 (sl) |
RU (1) | RU2708311C2 (sl) |
SG (2) | SG10201809379UA (sl) |
SI (2) | SI3134432T1 (sl) |
WO (1) | WO2015164759A2 (sl) |
ZA (2) | ZA201607174B (sl) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
EP2925864B1 (en) | 2012-11-27 | 2018-10-31 | The Children's Medical Center Corporation | Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction |
SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
MX2016013832A (es) | 2014-04-25 | 2017-03-09 | Children´S Medical Center Corp | Composiciones y metodos para tratar hemoglobinopatias. |
DK3689899T3 (da) * | 2014-04-25 | 2021-11-22 | 2Seventy Bio Inc | Kimære mnd-promotor-antigenreceptorer |
DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
WO2015188119A1 (en) | 2014-06-06 | 2015-12-10 | Bluebird Bio, Inc. | Improved t cell compositions |
AU2015292590B2 (en) * | 2014-07-24 | 2020-01-16 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
WO2016034666A1 (en) | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
NZ733025A (en) | 2014-12-12 | 2022-01-28 | 2Seventy Bio Inc | Bcma chimeric antigen receptors |
EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
WO2016182917A1 (en) | 2015-05-08 | 2016-11-17 | Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2017007994A1 (en) | 2015-07-08 | 2017-01-12 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
WO2017075237A2 (en) * | 2015-10-27 | 2017-05-04 | Celltheon Corporation | Chimeric post-transcriptional regulatory element |
CN116162658A (zh) * | 2015-11-19 | 2023-05-26 | 诺华股份有限公司 | 用于稳定慢病毒制剂的缓冲液 |
EP3380620B1 (en) | 2015-11-23 | 2024-07-03 | Novartis AG | Optimized lentiviral transfer vectors and uses thereof |
WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
CN108883100B (zh) | 2016-01-15 | 2022-11-25 | 美国基因技术国际有限公司 | 用于活化γ-δT细胞的方法和组合物 |
CN107034193B (zh) * | 2016-02-03 | 2020-06-05 | 北京马力喏生物科技有限公司 | 治疗b细胞白血病及b细胞淋巴瘤的治疗组合物 |
JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Hivワクチン接種および免疫療法 |
EP4036231A1 (en) | 2016-03-09 | 2022-08-03 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
US11976292B2 (en) | 2016-06-08 | 2024-05-07 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
CN105907790A (zh) * | 2016-06-21 | 2016-08-31 | 林志国 | 特异性识别EGFRvⅢ的含CD70嵌合抗原受体修饰T细胞的制备方法 |
AU2017292582C1 (en) | 2016-07-08 | 2021-11-11 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
WO2018017882A1 (en) | 2016-07-21 | 2018-01-25 | American Gene Technologies International Inc. | Viral vectors for treating parkinson's disease |
CA3034094A1 (en) | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
WO2018052142A1 (ja) * | 2016-09-16 | 2018-03-22 | キッセイ薬品工業株式会社 | 遺伝子改変細胞及びその作製方法 |
EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
EP3577134A1 (en) | 2017-01-31 | 2019-12-11 | Novartis AG | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
US10404635B2 (en) | 2017-03-21 | 2019-09-03 | Bank Of America Corporation | Optimizing data replication across multiple data centers |
AU2018245749A1 (en) | 2017-03-27 | 2019-10-03 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
KR20240057444A (ko) | 2017-03-27 | 2024-05-02 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
EP3600448A4 (en) * | 2017-03-29 | 2021-01-27 | Bluebird Bio, Inc. | VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
WO2018187231A2 (en) | 2017-04-03 | 2018-10-11 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018218135A1 (en) | 2017-05-25 | 2018-11-29 | The Children's Medical Center Corporation | Bcl11a guide delivery |
AU2018279085A1 (en) * | 2017-06-07 | 2019-12-05 | Region Of Southern Denmark | T cells expressing a chimeric antigen receptor |
JP2021501570A (ja) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
TW201922774A (zh) | 2017-11-15 | 2019-06-16 | 瑞士商諾華公司 | 標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法 |
EP3717907A1 (en) | 2017-11-30 | 2020-10-07 | Novartis AG | Bcma-targeting chimeric antigen receptor, and uses thereof |
CN109609533B (zh) * | 2017-12-27 | 2020-07-10 | 赛德特生物科技开发有限公司 | 基于人源化cd276抗体的car慢病毒表达载体构建及其应用 |
CN109608547B (zh) * | 2017-12-29 | 2022-03-15 | 郑州大学第一附属医院 | 表达Her2的嵌合抗原受体、慢病毒表达载体及其应用 |
WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
US20210054086A1 (en) * | 2018-01-10 | 2021-02-25 | The General Hospital Corporation | Immune cells expressing a chimeric antigen receptor |
BR112020014446A2 (pt) * | 2018-01-15 | 2020-12-29 | Pfizer Inc. | Métodos para administrar imunoterapia de receptor de antígeno quimérico em combinação com agonista de 4-1bb |
US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
EP3752203A1 (en) | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
CN108384760B (zh) * | 2018-03-16 | 2020-07-07 | 北京多赢时代转化医学研究院 | 携带cd20/cd19双特异性嵌合抗原受体的人t淋巴细胞及制备方法和应用 |
GB201807870D0 (en) * | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
US20210261659A1 (en) * | 2018-06-14 | 2021-08-26 | Bluebird Bio, Inc. | Cd79a chimeric antigen receptors |
MX2021000934A (es) * | 2018-07-26 | 2021-05-27 | Nanjing Legend Biotech Co Ltd | Linfocitos t que contienen nef y métodos para producirlos. |
EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
US20220364055A1 (en) | 2018-08-31 | 2022-11-17 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
EP3897745A1 (en) | 2018-12-23 | 2021-10-27 | CSL Behring LLC | Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome |
SG11202107825WA (en) | 2019-02-25 | 2021-09-29 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
CN109721659B (zh) * | 2019-03-11 | 2020-06-23 | 浙江玉安康瑞生物科技有限公司 | 一种靶向cd19的新型嵌合抗原受体(car)及其应用 |
WO2020191358A1 (en) * | 2019-03-20 | 2020-09-24 | Bluebird Bio, Inc. | Adoptive cell therapy |
US20230074800A1 (en) | 2019-03-21 | 2023-03-09 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
CN114206936A (zh) * | 2019-06-14 | 2022-03-18 | 2赛文缇生物公司 | 用于治疗癌症的组合物和方法 |
AR120566A1 (es) | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quiméricos y sus usos |
CN112980886B (zh) * | 2019-12-02 | 2022-02-22 | 河北森朗生物科技有限公司 | 一种能高效制备且应用安全的嵌合抗原受体t细胞及其制备方法与应用 |
CN115397460A (zh) | 2020-02-27 | 2022-11-25 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
KR20220146530A (ko) | 2020-02-27 | 2022-11-01 | 노파르티스 아게 | 키메라 항원 수용체-발현 세포의 제조 방법 |
CA3159639A1 (en) * | 2020-03-20 | 2021-09-23 | Lyell Immunopharma, Inc. | Novel recombinant cell surface markers |
WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
EP4175717A4 (en) * | 2020-07-02 | 2024-07-31 | Avrobio Inc | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS |
EP4051265A4 (en) | 2020-07-20 | 2022-12-28 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS |
IL300489A (en) | 2020-08-21 | 2023-04-01 | Novartis Ag | Compositions and methods for in vivo production of CAR expressing cells |
US11352363B1 (en) | 2020-11-23 | 2022-06-07 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
US11384090B2 (en) | 2020-11-23 | 2022-07-12 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
US11976084B2 (en) | 2020-11-23 | 2024-05-07 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
WO2022180586A1 (en) * | 2021-02-25 | 2022-09-01 | Senthil Natesan | Car t-cell product and method of preparation thereof |
EP4330381A1 (en) | 2021-04-27 | 2024-03-06 | Novartis AG | Viral vector production system |
US11319325B1 (en) | 2021-05-11 | 2022-05-03 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
US11339170B1 (en) | 2021-07-23 | 2022-05-24 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
US11325916B1 (en) | 2021-07-29 | 2022-05-10 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
EP4384549A1 (en) * | 2021-08-12 | 2024-06-19 | Cellogen Therapeutics Pvt. Ltd. | Chimeric antigen receptors (car) for b cell malignancies |
AR126838A1 (es) | 2021-08-20 | 2023-11-22 | Novartis Ag | Métodos para preparar células que expresan receptores de antígeno quiméricos |
WO2023133358A2 (en) * | 2022-01-10 | 2023-07-13 | 2Seventy Bio, Inc. | Muc16 chimeric antigen receptors |
WO2023230524A1 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vi, Llc | Compositions of secretory and/or catalytic cells and methods using the same |
WO2024073111A2 (en) * | 2022-09-30 | 2024-04-04 | Adicet Therapeutics, Inc. | Affinity binding entities directed to b7h6 and methods of use thereof |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
DE3843571A1 (de) | 1988-01-09 | 1989-07-20 | Asta Pharma Ag | 1,2-bis(aminomethyl)cyclobutan-platin-komplexe |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU7154891A (en) | 1989-12-01 | 1991-06-26 | Randall Kevin Mitchell | Photoelectric joystick displacement detector |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
DE4415263C1 (de) | 1994-04-15 | 1995-11-30 | Asta Medica Ag | Cis-[trans-1,2-Cyclobutanbis(methylamin)-N,N']-[(2S)-lactato-O·1·, O·2·]-platin(II)-trihydrat (Lobaplatin-Trihydrat), seine Herstellung und arzneiliche Verwendung |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
IL125884A0 (en) | 1996-03-04 | 1999-04-11 | Targeted Genetics Corp | Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes |
US20020177125A1 (en) | 1997-03-04 | 2002-11-28 | Kamb Carl Alexander | Human rhinovirus assays, and compositions therefrom |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
DE10132502A1 (de) | 2001-07-05 | 2003-01-23 | Gsf Forschungszentrum Umwelt | Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen |
US7638325B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
DK1623017T3 (da) | 2003-05-08 | 2011-01-10 | Life Technologies Corp | Frembringelse og isolering af antigenspecifikke T-celler |
JP5070045B2 (ja) | 2004-05-27 | 2012-11-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規人工抗原提示細胞およびそれらの用途 |
FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
US7260418B2 (en) | 2004-09-29 | 2007-08-21 | California Institute Of Technology | Multi-element phased array transmitter with LO phase shifting and integrated power amplifier |
GB0503936D0 (en) | 2005-02-25 | 2005-04-06 | San Raffaele Centro Fond | Method |
CN101238218A (zh) | 2005-05-20 | 2008-08-06 | 维克西斯公司 | 初级细胞的转导 |
WO2007018318A1 (ja) | 2005-08-10 | 2007-02-15 | National University Corporation Kanazawa University | 小脳星状細胞及び/又は籠細胞特異的な遺伝子発現方法 |
EP2094837B1 (en) | 2006-12-14 | 2012-04-25 | Medical Research Council | Use of pi3k, m-tor and akt inhibitors to induce foxp3 expression and generate regulatory t cells |
AU2008262487B2 (en) | 2007-05-23 | 2013-10-31 | Sangamo Therapeutics, Inc. | Methods and compositions for increased transgene expression |
WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
RS53782B1 (en) | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS |
HUE029619T4 (en) | 2009-03-10 | 2017-07-28 | Biogen Ma Inc | Anti-bcma antibodies |
US8999398B2 (en) | 2009-11-06 | 2015-04-07 | Transtarget Inc. | Polyclonal bispecific antibody compositions and method of use |
GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
ES2700966T3 (es) | 2010-12-09 | 2019-02-20 | Univ Pennsylvania | Utilización de linfocitos T modificados con receptores de antígeno quiméricos para tratar el cáncer |
EA201391059A1 (ru) | 2011-01-18 | 2014-05-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиции для лечения рака и способы их применения |
CN103502438A (zh) | 2011-03-23 | 2014-01-08 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
EP2697367B1 (en) | 2011-04-13 | 2018-12-19 | Immunicum AB | Method for proliferation of antigen-specific t cells |
EP3492108A1 (en) | 2011-06-10 | 2019-06-05 | Bluebird Bio, Inc. | Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
BR112014020499A2 (pt) | 2012-02-22 | 2019-09-24 | Univ Pennsylvania | sequência de ácido nucleico isolada, célula - t, vetor, e, população persistente de células - t |
RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
AU2013204923A1 (en) * | 2012-06-21 | 2014-01-16 | Anthrogenesis Corporation | Modified t lymphocytes having improved specificity |
MX370495B (es) | 2012-07-13 | 2019-12-13 | Univ Pennsylvania | Métodos para evaluar la conveniencia de células t transducidas para administración. |
SI2884999T1 (sl) * | 2012-08-20 | 2021-05-31 | Fred Hutchinson Cancer Research Center | Metoda in sestavki za celično imunoterapijo |
AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
EP2711418B1 (en) | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
NZ746914A (en) | 2012-10-02 | 2020-03-27 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
US9598489B2 (en) * | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
ES2824024T3 (es) | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
US20150329640A1 (en) | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
ES2814962T3 (es) | 2013-02-20 | 2021-03-29 | Novartis Ag | Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123 |
ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
JP6772063B2 (ja) | 2014-02-14 | 2020-10-21 | ベリカム ファーマシューティカルズ, インコーポレイテッド | 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法 |
AU2015248956B2 (en) | 2014-04-14 | 2020-06-25 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
DK3689899T3 (da) | 2014-04-25 | 2021-11-22 | 2Seventy Bio Inc | Kimære mnd-promotor-antigenreceptorer |
EP3134434A4 (en) | 2014-04-25 | 2017-10-25 | Bluebird Bio, Inc. | Kappa/lambda chimeric antigen receptors |
EP3134095B1 (en) | 2014-04-25 | 2020-04-22 | Bluebird Bio, Inc. | Improved methods for manufacturing adoptive cell therapies |
WO2015188119A1 (en) | 2014-06-06 | 2015-12-10 | Bluebird Bio, Inc. | Improved t cell compositions |
AU2015292590B2 (en) | 2014-07-24 | 2020-01-16 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
NZ733025A (en) | 2014-12-12 | 2022-01-28 | 2Seventy Bio Inc | Bcma chimeric antigen receptors |
WO2016164408A1 (en) | 2015-04-06 | 2016-10-13 | The General Hospital Corporation | Anti-cspg4 reagents and methods of treating cancer |
WO2016187216A1 (en) * | 2015-05-18 | 2016-11-24 | Bluebird Bio, Inc. | Anti-ror1 chimeric antigen receptors |
WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
CN112980886B (zh) * | 2019-12-02 | 2022-02-22 | 河北森朗生物科技有限公司 | 一种能高效制备且应用安全的嵌合抗原受体t细胞及其制备方法与应用 |
-
2015
- 2015-04-24 DK DK19218258.2T patent/DK3689899T3/da active
- 2015-04-24 RS RS20200339A patent/RS60106B1/sr unknown
- 2015-04-24 SG SG10201809379UA patent/SG10201809379UA/en unknown
- 2015-04-24 LT LTEP15782739.5T patent/LT3134432T/lt unknown
- 2015-04-24 ES ES19218258T patent/ES2899608T3/es active Active
- 2015-04-24 CN CN201911324554.6A patent/CN110938655A/zh active Pending
- 2015-04-24 PL PL15782739T patent/PL3134432T3/pl unknown
- 2015-04-24 CN CN201580031860.4A patent/CN106536549B/zh active Active
- 2015-04-24 KR KR1020167032984A patent/KR102021982B1/ko active IP Right Grant
- 2015-04-24 SI SI201531177T patent/SI3134432T1/sl unknown
- 2015-04-24 HU HUE15782739A patent/HUE048898T2/hu unknown
- 2015-04-24 LT LTEP19218258.2T patent/LT3689899T/lt unknown
- 2015-04-24 KR KR1020197026360A patent/KR102135006B1/ko active IP Right Grant
- 2015-04-24 BR BR112016024481A patent/BR112016024481A2/pt active Search and Examination
- 2015-04-24 EP EP15782739.5A patent/EP3134432B1/en active Active
- 2015-04-24 PT PT157827395T patent/PT3134432T/pt unknown
- 2015-04-24 ES ES15782739T patent/ES2781073T3/es active Active
- 2015-04-24 WO PCT/US2015/027539 patent/WO2015164759A2/en active Application Filing
- 2015-04-24 EP EP21198992.6A patent/EP3998278A1/en active Pending
- 2015-04-24 HU HUE19218258A patent/HUE056735T2/hu unknown
- 2015-04-24 PT PT192182582T patent/PT3689899T/pt unknown
- 2015-04-24 PL PL19218258T patent/PL3689899T3/pl unknown
- 2015-04-24 HR HRP20211910TT patent/HRP20211910T1/hr unknown
- 2015-04-24 IL IL296691A patent/IL296691B2/en unknown
- 2015-04-24 SG SG11201608754SA patent/SG11201608754SA/en unknown
- 2015-04-24 RU RU2016145958A patent/RU2708311C2/ru active
- 2015-04-24 NZ NZ725169A patent/NZ725169A/en unknown
- 2015-04-24 JP JP2016564004A patent/JP6538716B2/ja active Active
- 2015-04-24 CA CA2946585A patent/CA2946585C/en active Active
- 2015-04-24 US US15/306,724 patent/US10774343B2/en active Active
- 2015-04-24 RS RS20211468A patent/RS62733B1/sr unknown
- 2015-04-24 AU AU2015249390A patent/AU2015249390B2/en active Active
- 2015-04-24 EP EP19218258.2A patent/EP3689899B8/en active Active
- 2015-04-24 DK DK15782739.5T patent/DK3134432T3/da active
- 2015-04-24 MX MX2016013964A patent/MX2016013964A/es unknown
- 2015-04-24 SI SI201531750T patent/SI3689899T1/sl unknown
-
2016
- 2016-10-13 IL IL248348A patent/IL248348B/en active IP Right Grant
- 2016-10-18 ZA ZA2016/07174A patent/ZA201607174B/en unknown
- 2016-10-24 MX MX2021005490A patent/MX2021005490A/es unknown
-
2018
- 2018-03-06 JP JP2018039423A patent/JP6606210B2/ja active Active
-
2019
- 2019-02-14 ZA ZA2019/00944A patent/ZA201900944B/en unknown
- 2019-11-08 AU AU2019261783A patent/AU2019261783C1/en active Active
-
2020
- 2020-03-24 HR HRP20200483TT patent/HRP20200483T1/hr unknown
- 2020-03-24 CY CY20201100277T patent/CY1122831T1/el unknown
- 2020-08-07 US US16/987,768 patent/US20210032658A1/en active Pending
-
2021
- 2021-06-09 IL IL283828A patent/IL283828B2/en unknown
-
2022
- 2022-01-11 CY CY20221100027T patent/CY1125032T1/el unknown
- 2022-05-12 AU AU2022203195A patent/AU2022203195A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283828A (en) | chimeric antigen receptors mnd promoter | |
IL250536A0 (en) | Chimeric antigen receptors | |
HK1245801B (zh) | Bcma嵌合抗原受體 | |
IL251030A0 (en) | Chimeric antigen receptors | |
IL250202B (en) | bcma chimeric antigen receptors | |
SI3230310T1 (sl) | Anti-CD70 himerni antigenski receptorji | |
GB201617290D0 (en) | Novel chimeric antigen receptors |